Article Text

Download PDFPDF
Short report
The use of generic immunosuppression for transplant patients: a UK perspective
  1. Andrea Devaney1,
  2. Mark Lee2
  1. 1Oxford Transplant Centre, Oxford University Hospitals NHS Trust, UK
  2. 2Pharmacy Department, Leeds Teaching Hospitals, St James's University Hospital, Leeds, UK
  1. Correspondence to Mrs Andrea Devaney, Oxford Transplant Centre, Oxford University Hospitals NHS Trust, The Churchill, Headington, Oxford OX3 7LE, UK; andrea.devaney{at}


Generic immunosuppression is not a new phenomenon to solid organ transplantation; however, clinical and patient safety concerns have been raised with the introduction onto the market of multiple brands of generic ciclosporin, tacrolimus and mycophenolate mofetil. In the UK there are significant national drivers to support efficiency savings within the National Health Service (NHS) and thus allow reimbursement back into clinical services to continually improve quality of patient care. The use of generic immunosuppression to release such savings must be given serious consideration. In the UK, many transplant centres have safely implemented the use of generic tacrolimus and mycophenolate mofetil brands into clinical practice in both de novo and established renal transplant recipients.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.